Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.47 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.43 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.43 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.43 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.42 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.42 |
| ▸ | HRH1 | P35367 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4237305 | 0.86 | HRH3 (0.61) | HRH3KCNH2GRIN2B | |
| SCHEMBL25758209 | 0.82 | CARM1 (0.56) | MAOBHRH3KCNH2 | |
| SCHEMBL27580519 | 0.82 | ALDH1A1 (0.48) | MAOBHRH3KCNH2PTGER4PTGER2 | |
| SCHEMBL4240603 | 0.80 | HRH3 (0.51) | HRH3KCNH2 | |
| SCHEMBL7733543 | 0.78 | RARB (0.53) | MAOBHRH3PTGER4PTGER2PTGER3 | |
| SCHEMBL7733538 | 0.78 | RARB (0.53) | MAOBHRH3PTGER4PTGER2PTGER3 | |
| SCHEMBL10884241 | 0.78 | ALDH1A1 (0.50) | MAOBHRH3PTGER4PTGER2PTGER3 | |
| SCHEMBL10884236 | 0.78 | ALDH1A1 (0.50) | MAOBHRH3PTGER4PTGER2PTGER3 | |
| SCHEMBL4235476 | 0.77 | BCHE (0.47) | HRH3 | |
| SCHEMBL4238396 | 0.77 | HRH3 (0.53) | HRH3KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | CEREP (FR) | 2009-09-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090233910-A1 | Npy antagonists, preparation and uses | NPY1R, NPY5R, NPY2R | MAOB 169/4885HRH3 210/4885KCNH2 1304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.